Table 2.

Associations between viral suppression (<400 copies/mL by 24 weeks) and adherence defined by medication return (MR) at different thresholds (60–99%) for each drug individually and for the regimen as whole stratified by regimen

LPV/r-based regimen
Adherence level	LPV/r			Lamivudine			Stavudine			Largest MR*
	OR	95% CI	p-value	OR	95% CI	p-value	OR	95% CI	p-value	OR	95% CI	p-value
60%	3.18	1.10, 9.22	0.03	2.73	0.86, 8.65	0.09	3.04	1.05, 8.81	0.04	2.74	1.28–5.86	0.01
70%	2.54	0.92, 7.06	0.07	2.85	0.98, 8.33	0.06	2.49	1.04, 5.92	0.04	2.88	1.38–6.03	0.00
80%	3.25	1.49, 7.06	0.00	3.00	1.28, 7.04	0.01	1.74	0.80, 3.79	0.16	2.23	1.13–4.39	0.02
85%	2.24	1.06, 4.74	0.03	2.94	1.41, 6.13	0.00	1.91	0.98, 3.70	0.06	2.30	1.30–4.07	0.00
90%	1.96	0.93, 4.14	0.08	2.17	1.06, 4.46	0.04	1.79	0.96, 3.36	0.07	1.71	0.95–3.08	0.07
95%	2.19	1.13, 4.26	0.02	1.75	0.87, 3.51	0.12	1.51	0.82, 2.76	0.18	1.65	0.95–2.85	0.07
99%	2.22	1.23, 4.00	0.01	1.72	0.87, 3.38	0.12	1.26	0.76, 2.09	0.38	1.52	0.93–2.50	0.10

Ritonavir-based regimen
Adherence level	Ritonavir			Lamivudine			Stavudine			Largest MR
	OR	95% CI	p-value	OR	95% CI	p-value	OR	95% CI	p-value	OR	95% CI	p-value
60%	1.24	0.27, 5.61	0.78	0.44	0.09, 2.19	0.31	0.50	0.10–2.41	0.39	0.71	0.23–2.17	0.54
70%	1.09	0.37, 3.26	0.87	0.29	0.06, 1.36	0.12	1.10	0.29, 3.51	0.98	0.79	0.34–1.81	0.58
80%	1.51	0.66, 3.45	0.32	0.49	0.17, 1.43	0.19	1.79	0.77, 4.14	0.17	1.46	0.77–2.75	0.25
85%	2.00	1.03, 3.85	0.04	0.70	0.27, 1.78	0.45	1.40	0.67, 2.95	0.37	1.41	0.80–2.48	0.24
90%	1.78	0.97, 3.30	0.06	0.75	0.33, 1.75	0.51	1.73	0.90, 3.31	0.10	1.41	0.83–2.39	0.20
95%	1.28	0.72, 2.27	0.40	0.82	0.39, 1.70	0.59	1.36	0.78, 2.36	0.28	1.10	0.67–1.81	0.72
99%	1.26	0.75, 2.10	0.38	0.90	0.46, 1.74	0.75	1.24	0.77, 1.99	0.37	1.20	0.77–1.87	0.42

^*Largest MR = For each visit with at least one MR, the most non-adherent MR was used to classify adherence level for the visit